Background {#Sec1}
==========

Gastro-intestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastro-intestinal tract. However they are very rare, accounting for about 1% of the tumors of the gastro-intestinal tract. These tumors originate from the interstitial cells of Cajal or other common cell precursors which express tyrosine kinase receptors (type III). They are sometimes called the pacemaker cells of the gut. Treatment consists of surgical resection with or without adjuvant/neo-adjuvant therapy with an oral multi-kinase inhibitor like regorafinib \[[@CR1]--[@CR3]\].

Regorafenib is an oral multi-kinase inhibitor used to treat metastatic GISTs after progression on standard treatment. It significantly improve progression-free survival compared with placebo in patients \[[@CR3]\]. To our knowledge this is the first case in literature to show the response of regorafenib on ^18^F--FDG PET/CT.

Case presentation {#Sec2}
=================

A 37-year-old male complaining about lower abdominal pain and weight loss was referred to our hospital. He reported a weight loss of 5 kg in the last 3 months. An abdominal ultrasound and computed tomography (CT) were performed as work-up. Both examinations showed diffuse peritoneal implants.

Discussion {#Sec222}
==========

Surgical exploration and debulking was performed to obtain a tumor specimen for histopathological examination. Histological examination of this specimen showed a GIST with c-KIT exon 11 deletion (c.1708_1728del). As ^18^F--FDG PET has been shown of significant value in evaluating treatment response in GISTs, high dose contrast-enhanced ^18^F--FDG PET/CT scans (374.9 ± 17.2 MBq; approximately 60 min after tracer injection) were performed both before treatment and after every therapy switch to evaluate treatment response \[[@CR4]\]. ^18^FDG-PET/CT performed for tumor staging showed multiple tumor localizations in the small bowel, the sigmoid and mesenterium without signs of extra-abdominal disease. Treatment with imatinib 400 mg daily was started with follow-up ^18^F--FDG PET/CT 2 months later showing disease progression. The dose was increased to 800 mg daily but follow-up ^18^F--FDG PET/CT 3 months later again revealed disease progression. A switch to sunitinib 50 mg once a day was performed. Upon further disease progression on the ^18^F--FDG PET/CT 10 months later, third line treatment with regorafenib 160 mg/day was initiated with a mixed response on ^18^F--FDG-PET/CT 4 months after treatment initiation with regorafinib (Fig. [1](#Fig1){ref-type="fig"}). There was one lesion with a complete metabolic response (CR), one with a partial metabolic response (PMR) and one with stable disease (SD) according to the EORTC criteria for ^18^F--FDG-PET response \[[@CR5]\].Fig. 1Maximal intensity projection (MIP) images of the ^18^F--FDG-PET scan at baseline and after regorafenib treatment. CR = complete response; SD = stable disease; Deep PMR = deep partial metabolic response

Pre- and post-therapy with regorafinib fused PET/CT and CT images with the differences in maximal standardized uptake value (ΔSUV~max~) and differences in maximal diameter (Δdiam~max~) are shown in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}. The lesion with complete metabolic response had a ΔSUV~max~ of − 91% and a Δdiam~max~ of − 1.7%. The lesion with the partial metabolic response had a ΔSUV~max~ of − 56% and a Δdiam~max~ of − 21%. Both lesions were stable disease on CT scan according to the RECIST1.1 criteria. \[[@CR6]\]. The lesion with stable disease on PET had a ΔSUV~max~ of − 8.0% and a Δdiam~max~ of − 3.3%. The total volume of the lesion with complete metabolic response was 19.9 cm^3^ pretherapy and 17.6 cm^3^ posttherapy. The lesions with partial metabolic response and stable disease did not change in volume and were respectively 4.1 cm^3^ and 3.6 cm^3^. The volume of the new lesion was 3.2 cm^3^. No histological confirmation of this new lesion was obtained due to the general condition of the patient. However, this lesion increased both in volume and metabolism on follow-up scans, compatible with a true positive new tumoral lesion.Fig. 2Pre- and post-therapy fused PET/CT and CT images of the different lesions. NAC = non-attenuation-corrected imagesFig. 3Pre- and post-therapy fused PET/CT and CT images of the different lesions

Besides these previously known lesions, a new hypermetabolic lesion was seen on the non-attenuation-corrected (NAC) ^18^F--FDG-PET images. It corresponded to a new hypodense liver lesion on CT, implying a new liver metastasis. However, the lesion was not visible on the attenuation-corrected (AC) and MIP images because of breathing motion-induced misregistration and subsequent lung density attenuation correction, which strongly reduces the apparent uptake in the lesion. This lesion has important consequences for the patient with regard to further treatment options (switch to another tyrosine kinase inhibitor) and illustrates the importance to look at NAC images on all oncological scans, in particular not to miss liver lesions within the liver dome \[[@CR7], [@CR8]\].

Conclusion {#Sec3}
==========

This case illustrates that metabolic response to third line regorafinib treatment can occur in GIST lesions without morphological response. Therefore, even though it did not affect treatment decision in this case, this finding highlights the importance of ^18^F--FDG PET scans in the evaluation of treatment response in future GIST tumors cases.

18F-FDG PET

:   \[18\]Fluor-Fluorodeoxyglucose Positron Emission Tomography

AC

:   Attenuation-corrected

c.1708_1728del

:   c-KIT exon 11 deletion

CR

:   Complete metabolic response

CT

:   Computed tomography

GISTs

:   Gastro-intestinal stromal tumors

MIP

:   Maximal intensity projection

NAC

:   Non-attenuation-corrected

PMR

:   Partial metabolic response

RECIST

:   Respons Evaluation Criteria in Solid Tumours

SD

:   Stable disease

Δdiam~max~

:   Maximal diameter

ΔSUV~max~

:   Maximal standardized uptake value

We have no acknowledgments to be made.

Funding {#FPar1}
=======

No funding for this case report was received.

Availability of data and materials {#FPar2}
==================================

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

All authors contributed to the manuscript in order of publication. DVW contributed to the conception, design, acquisition, analysis and interpretation of data, drafted the manuscript, gave final approve and agreed to be accountable for all aspects of the work. OG: contributed to the conception, design, acquisition, gave final approve and agreed to be accountable for all aspects of the work. VV: contributed to the acquisition, gave final approve and agreed to be accountable for all aspects of the work. PS: contributed to the acquisition, gave final approve and agreed to be accountable for all aspects of the work. KVL: contributed to the acquisition, gave final approve and agreed to be accountable for all aspects of the work. CMD: contributed to the conception, design, acquisition, analysis and interpretation of data, has been involved in drafting the manuscript, gave final approve and agreed to be accountable for all aspects of the work.

Ethics approval and consent to participate {#FPar3}
==========================================

This study was approved by the Ethics Committee UZ Leuven. Informed written consent from the patient was received.

Consent for publication {#FPar4}
=======================

Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
